Shire receives complete-response letter for Intuniv

07/28/2009 | Reuters

The FDA deferred its approval decision on extended-release Intuniv, Shire's drug candidate for attention-deficit/hyperactivity disorder, because of unresolved labeling discussions. Shire said the company remains confident that the treatment will be approved in the fourth quarter.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX